ProCE Banner Activity

No Increase in Adverse Birth Outcomes Following Exposure to Raltegravir in Pregnancy

Slideset Download
Conference Coverage
Prospective data on birth outcomes demonstrate no increase in rates of spontaneous abortions, stillbirths, neural tube defects, or other congenital anomalies with raltegravir use at conception or during pregnancy.

Released: November 18, 2019

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

Supported by educational grants from

Gilead

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare